Interaction Guide · Research summary

Can I take Piper Methysticum with Iloperidone?

Review Piper Methysticum with Iloperidone: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Review kava before adding it to iloperidone, especially if you already feel sleepy, dizzy or unsteady. The exact combination’s risk has not been quantified.

What this answer covers

Oral kava supplement with oral tablets; botanical preparation and medicine route retained.

Supplement or preparation
Piper methysticum
Medication ingredient
iloperidone

Why alertness deserves review

Iloperidone has cognitive or motor impairment precautions. Kava guidance raises alertness concerns, so your symptoms and other medicines matter.

A negative driving result has limits

A small study found no driving impairment with its kava preparation compared with placebo. Oxazepam was a separate comparator, not a combined exposure with this medicine.

Identify the complete product

Bring the amount, preparation and other ingredients to the pharmacist. These sources do not provide a universal safe dose or a protective gap between the supplement and medicine.

Watch for impaired alertness

Iloperidone can affect alertness and coordination. Avoid driving if affected and contact the prescriber if added sleepiness, confusion or unsteadiness appears after a new product. Severe confusion, fainting or inability to wake needs urgent assessment.

Evidence and practical considerations

Side effects & toxicity

Conditional alertness review based on exact medication effects and supplement precautions; not proven pair-specific CNS depression.

Exact scope
Oral kava supplement with oral tablets; botanical preparation and medicine route retained. with Exact iloperidone oral tablets. Exact RxNorm IN73178; oral iloperidone tablets. CYP2D6/CYP3A4 and QT precautions, not automatic electrolyte supplementation.
Medication form and route
oral
Timing or duration
Source-specific single-dose, repeated-dose and observational exposures distinguished.

What remains uncertain

  • No exact-pair co-use trial identified; standalone or other-medicine findings and product differences prevent a uniform risk estimate.

Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.

Research conclusion: supported with conditions · Evidence assessment: low

Read the supporting source summaries

Source 1: current product label

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: People prescribed iloperidone.

Orthostatic hypotension, sedation, QT prolongation and baseline/periodic potassium-magnesium monitoring in at-risk patients; CYP2D6/CYP3A4 inhibitor sensitivity.

How this applies: Exact RxNorm IN73178; oral iloperidone tablets. CYP2D6/CYP3A4 and QT precautions, not automatic electrolyte supplementation.

No supplement-specific event rate, universal timing rule or untested route/preparation equivalence.

Source 2: official guidance

nccih.nih.gov · Source check Sep 10, 2026

Population: People considering the specified supplement.

Advises against use with sedative substances. Kava may cause dizziness and has been linked to rare severe liver injury, including with different extraction methods.

How this applies: Preparation-specific evidence; exact iloperidone co-use is not inferred from another medicine or route.

Not a iloperidone study. Intrinsic liver risk does not establish added iloperidone hepatotoxicity; preparation and co-exposure vary.

Source 3: original human study

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: Twenty-two adults in a randomized crossover driving study.

Medicinal-dose kava did not significantly impair driving outcomes; oxazepam impaired some outcomes.

How this applies: Preparation-specific evidence; exact iloperidone co-use is not inferred from another medicine or route.

Not combined administration or evidence that all kava preparations lack impairment.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Research summary published
Article prepared
Current exact available claims adjudicated using original captures and explicit identity and comparator limits.

Article revision: 2cfd638275df2158

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.